Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05880537 · ClinicalTrials.gov registry record
Decellularized Femoral Artery Allograft (Nexeon AVX) Prospective Registry
A clinical trial of End Stage Renal Disease, sponsored by LifeNet Health.
- Recruiting
- Registry status
- 100
- Enrollment target
- 4
- Study locations
NCT05880537 is a study of End Stage Renal Disease that is actively recruiting participants, run by LifeNet Health. The registered enrollment target is 100 participants, below the 832-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (88% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT05880537, a study of End Stage Renal Disease, is actively recruiting participants, sponsored by LifeNet Health.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 4
- Study locations
Study Summary
Post market registry to assess the safety and efficacy of a novel decellularized human femoral artery allograft (Nexeon AVX Decellularized Femoral Artery,
Conditions Studied
Interventions
- OTHER Nexeon Arterial Venous Allograft
Study Locations (4)
California
- Olive View - UCLA Medical Center - Sylmar
- Harbor-UCLA Medical Center - Torrance
Alabama
- Infirmary Heath - Mobile
Virginia
- Sentara Norfolk General Hospital - Norfolk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2023-06-06 |
| Est. Completion | 2027-12-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05880537
The ClinicalTrials.gov registry entry for NCT05880537 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 832-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (88% lower). The listed sponsor is LifeNet Health, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with End Stage Renal Disease appearing as the primary indexed condition, and to 1 intervention - of which Nexeon Arterial Venous Allograft is the first listed.
NCT05880537 reports 4 study locations spanning 3 distinct geographic areas - top geographies include California, Alabama, Virginia.
Frequently Asked Questions
What is clinical trial NCT05880537 about?
NCT05880537 is a clinical study titled "Decellularized Femoral Artery Allograft (Nexeon AVX) Prospective Registry". Post market registry to assess the safety and efficacy of a novel decellularized human femoral artery allograft (Nexeon AVX Decellularized Femoral Artery,
What is the current status of trial NCT05880537?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2023-06-06. Estimated completion is 2027-12-15.
What conditions does trial NCT05880537 study?
This clinical trial studies the following conditions: End Stage Renal Disease.
What interventions are being tested in trial NCT05880537?
The interventions under investigation include: Nexeon Arterial Venous Allograft (OTHER).
Who is sponsoring clinical trial NCT05880537?
This trial is sponsored by LifeNet Health, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05880537 being conducted?
This trial has 4 study locations across Alabama, California, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for End Stage Renal Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study
RECRUITING · NA
-
Drug Interaction Potential of Pro-Inflammatory Conditions
RECRUITING
-
PReSeRVE-HD: Observational Study of the Merit HeRO® Graft and Super HeRO® in Patients on Hemodialysis
RECRUITING
-
Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial
RECRUITING · NA
-
AMSC for Reducing Anastomotic Stenosis in Primary Arteriovenous Anastomoses
RECRUITING · Phase 1
-
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.